Merck & Co., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, United States of America.
Merck & Co., Inc., 770 Sumneytown Pike, WP45-1127, WP, Pennsylvania, 19486, United States of America.
AAPS J. 2022 Feb 11;24(1):34. doi: 10.1208/s12248-022-00685-2.
Analytical methods are utilized throughout the biopharmaceutical and vaccines industries to conduct research and development, and to help control manufacturing inputs and outputs. These analytical methods should continuously provide quality data to support decisions while managing the remaining of risk and uncertainty. Analytical quality by design (AQbD) can provide a systematic framework to achieve a continuously validated, robust assay as well as life cycle management. AQbD is rooted in ICH guidelines Q8 and Q9 that were translated to the analytical space through several white papers as well as upcoming USP 1220 and ICH Q14. In this white paper, we expand on the previously published concepts of AQbD by providing additional context for implementation in relation to ICH Q14. Using illustrative examples, we describe the AQbD workflow, its relation to traditional approaches, and potential pathways for ongoing, real-time verification. We will also discuss challenges with respect to implementation and regulatory strategies.
分析方法在生物制药和疫苗行业中被广泛应用于研发,以及帮助控制生产投入和产出。这些分析方法应该持续提供高质量的数据,以支持决策,同时管理剩余的风险和不确定性。分析质量源于设计(AQbD)可以为实现持续验证、稳健的检测以及生命周期管理提供系统框架。AQbD 植根于 ICH 指南 Q8 和 Q9,这些指南通过多份白皮书以及即将出台的 USP 1220 和 ICH Q14 被转化到分析领域。在本白皮书中,我们通过提供与 ICH Q14 相关的实施方面的更多背景信息,对 AQbD 的先前发布的概念进行了扩展。使用说明性示例,我们描述了 AQbD 工作流程、它与传统方法的关系以及实时验证的潜在途径。我们还将讨论实施和监管策略方面的挑战。